ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET

Company Participants

Al Kildani - Senior Vice President, Investor Relations and Corporate Communications
Steve Davis - President and Chief Executive Officer
Brendan Teehan - Chief Operating Officer, Head of Commercial
Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution
Mark Schneyer - Chief Financial Officer
Parag Meswani - Senior Vice President, Trofinetide
Elizabeth Thompson - Executive Vice President, Head of Research and Development

Conference Call Participants

Ritu Baral - TD Cowen
Charles Duncan - Cantor
Anish Nikhanj - RBC Capital Markets
Joel Beatty - Baird
Marc Goodman - Leerink
Jeff Hung - Morgan Stanley
Keith Tapper - BMO Capital Markets
David Hoang - Citigroup
Eddie Hickman - Guggenheim
Tessa Romero - JPMorgan

Operator

Good day ladies and gentlemen, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications, ACADIA. Please go ahead.

Al Kildani

Thank you, Daniel. Good afternoon and thank you for joining us on today's call to discuss ACADIA’S second quarter 2024 earnings. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks, followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, DAYBUE and NUPLAZID.

Also joining us is Elizabeth Thompson, PhD, Executive Vice President, Head Of Research and Development, will provide an update on our pipeline programs and Mark Schneier, our Chief Financial Officer, who will review the financial highlights. Steve will then provide some closing thoughts before we open up the call to your questions.

In addition, Parag Meswani, Senior Vice President, Trofinetide - Rare Disease Franchise, as well as Kimberly Manard, Senior Vice President, Global Strategic Planning and Execution will be available for the Q&A session. We are using supplemental slides which are available on our website's events and presentations section.

Before proceeding, I would like to remind you that during our call today we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth, potential, timing of events, future results, and financial guidance, are based on current information, assumptions and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change except as required by law.